{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:09:20Z","timestamp":1778944160056,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T00:00:00Z","timestamp":1521849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:p>\n                    Sodium\u2010glucose co\u2010transporter\u20102 (SGLT2) inhibitors and glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101RAs) are antihyperglycaemic agents with weight\u2010lowering effects. The efficacy and safety of the SGLT2 inhibitor canagliflozin as add\u2010on therapy in Japanese patients with type 2 diabetes mellitus (T2DM) and inadequate glycaemic control with a GLP\u20101RA (\u226512 weeks) were evaluated in this phase IV study. Patients received canagliflozin 100 mg once daily for 52 weeks. Efficacy endpoints included change in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP) and HDL cholesterol from baseline to week 52. Safety endpoints included adverse events (AEs), hypoglycaemia and laboratory tests. Of the 71 patients treated with canagliflozin, 63 completed the study. At 52 weeks, HbA1c was significantly reduced from baseline (\u22120.70%; paired\n                    <jats:italic>t<\/jats:italic>\n                    test,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .001). Significant changes were also observed in FPG (\u221234.7 mg\/dL), body weight (\u22124.46%), SBP (\u22127.90 mm Hg), and HDL cholesterol (7.60%; all\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .001). The incidence of AEs, adverse drug reactions and hypoglycaemia was 71.8%, 32.4% and 9.9%, respectively. All hypoglycaemic events were mild. These findings suggest that the long\u2010term combination of canagliflozin with a GLP\u20101RA is effective and well tolerated in Japanese patients with T2DM.\n                  <\/jats:p>","DOI":"10.1111\/dom.13267","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T05:32:49Z","timestamp":1519363969000},"page":"1770-1775","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and safety of canagliflozin as add\u2010on therapy to a glucagon\u2010like peptide\u20101 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52\u2010week, open\u2010label, phase IV study"],"prefix":"10.1111","volume":"20","author":[{"given":"Shin\u2010ichi","family":"Harashima","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition Kyoto University Graduate School of Medicine  Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuya","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition Kyoto University Graduate School of Medicine  Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuoki","family":"Kondo","sequence":"additional","affiliation":[{"name":"Ikuyaku Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Ikuyaku Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Ikuyaku Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Ikuyaku Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8875-7598","authenticated-orcid":false,"given":"Yumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Ikuyaku Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-6047.11.s8.19.x"},{"key":"e_1_2_6_3_1","unstructured":"Ministry of Health Labour and Welfare.Summary Results of the National Health and Nutrition Survey Japan 2012. 2015. Japanese.http:\/\/www.mhlw.go.jp\/file\/04\u2010Houdouhappyou\u201010904750\u2010Kenkoukyoku\u2010Gantaisakukenkouzoushinka\/kekkagaiyou.pdf. Accessed May 4 2017."},{"key":"e_1_2_6_4_1","unstructured":"Japan Diabetes Clinical Data Management Study Group.2014.Japanese.http:\/\/jddm.jp\/data\/index-2013.html. Accessed May 4 2017."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12090"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S90662"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12251"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12589"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30267-4"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0086-7"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12694"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12982"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.935764"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12266"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13152"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2258"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0355"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.11.001"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2534-0"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2625"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01536.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13267","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13267","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13267","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:05:14Z","timestamp":1761879914000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,24]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/dom.13267"],"URL":"https:\/\/doi.org\/10.1111\/dom.13267","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,24]]},"assertion":[{"value":"2017-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}